3.1. Participants
Twenty-three patients were assessed for study eligibility, six of whom refused to participate. In total, seventeen participants were included. Due to COVID-19 restrictions, we could not continue the inclusion of the up to twenty participants we aimed for. After the one-week baseline, ten participants received the intervention condition first, and seven received the control condition first. Participant characteristics are reported in 